Condition
Arginine Vasopressin Deficiency
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 7 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
7 shownIdentifying Oxytocin Deficiency in Pediatric Patients With Pituitary DiseaseNCT07568509 · 2026-08-17
RECRUITINGCopeptin Measurement After Mannitol and Hypertonic Saline for the Diagnosis of Polyuria-polydipsia SyndromeNCT07569861 · 2026-06-16
RECRUITINGEffects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency and Healthy ControlsNCT06808516 · 2025-07-01
RECRUITINGEffect of Intranasal Oxytocin on Emotion Recognition and Acute Psycho-Social Stress-induced Cortisol Increase in Patients With Central Diabetes Insipidus and Healthy ControlsNCT06676774 · 2025-05-16
RECRUITINGIdentifying Oxytocin Deficiency in Adults With Pituitary DiseaseNCT06460948 · 2024-11-13
COMPLETEDMannitol-induced Release of Copeptin in Healthy Adults and Patients With Polyuria-Polydipsia Syndrome (MARS Study)NCT06542198 · 2024-09-10
COMPLETEDPlasma Copeptin in Response to Oral Urea in Healthy Adults and Patients With Polyuria-polydipsia SyndromeNCT05890690 · 2023-06-02
COMPLETEDCommon interventions
Norethindrone Acetate-Ethinyl EstradiolDRUG2Oxytocin nasal sprayDRUG2Hypertonic SalineDIAGNOSTIC_TEST1MannitolDIAGNOSTIC_TEST1Mannitol Infusion (blinded)DIAGNOSTIC_TEST1Mannitol Infusion (open label)DIAGNOSTIC_TEST1PlaceboDIAGNOSTIC_TEST1PlaceboDRUG1PlaceboOTHER1Placebo Infusion (blinded)DIAGNOSTIC_TEST1UreaDIAGNOSTIC_TEST1
Leading sponsors
Trial status mix
RECRUITING4
COMPLETED3
Phase mix
NA3
EARLY_PHASE12
PHASE22
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.